Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Olumide B. Gbolahan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0598-4809; OpenAlex author ID A5051654669. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 9

  1. A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Co-author DOI 10.1016/j.canlet.2025.218233↗
  2. Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Ra… Co-author DOI 10.3390/cancers18111704↗
  3. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer. Co-author DOI 10.1002/cam4.5133↗
  4. Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer? Co-author DOI 10.1016/j.jss.2022.11.031↗
  5. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.amjsurg.2022.04.004↗
  6. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001972↗
  7. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. Co-author DOI 10.1186/s12885-019-5630-4↗
  8. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancrea… First author DOI 10.1097/coc.0000000000000409↗
  9. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. First author DOI 10.1158/1078-0432.ccr-18-1472↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Selwyn Maurice Vickers · 3 shared papers, 2022–2023 · strength 0.50
  2. Ahmer Irfan · 3 shared papers, 2022–2023 · strength 0.50
  3. John Bart Rose · 3 shared papers, 2022–2023 · strength 0.50
  4. Vikas Dudeja · 3 shared papers, 2022–2023 · strength 0.50
  5. Ravi Kumar Paluri · 2 shared papers, 2023–2026 · strength 0.49
  6. Bassel F. El‐Rayes · 2 shared papers, 2023–2026 · strength 0.42
  7. Sushanth Reddy · 2 shared papers, 2022–2023 · strength 0.32
  8. Hua Amanda Fang · 2 shared papers, 2022–2023 · strength 0.32
  9. Upender Manne · 1 shared paper, 2026 · strength 0.32
  10. Gagan Deep · 1 shared paper, 2026 · strength 0.32
  11. Ashish Manne · 1 shared paper, 2026 · strength 0.32
  12. Safi Shahda · 3 shared papers, 2018–2019 · strength 0.30
  13. Bert H. O’Neil · 3 shared papers, 2018–2019 · strength 0.30
  14. Neda Hashemi‐Sadraei · 2 shared papers, 2018–2023 · strength 0.27
  15. Chrystal M Paulos · 1 shared paper, 2026 · strength 0.24
  16. Emily R. Greene · 1 shared paper, 2026 · strength 0.24
  17. Cameron J. Herting · 1 shared paper, 2026 · strength 0.24
  18. Natalie K. Horvat · 1 shared paper, 2026 · strength 0.24
  19. Olatunji Boladale Alese · 1 shared paper, 2026 · strength 0.24
  20. Gregory B. Lesinski · 1 shared paper, 2026 · strength 0.24
  21. Maria Diab · 1 shared paper, 2026 · strength 0.24
  22. Amikar Sehdev · 2 shared papers, 2018–2019 · strength 0.21
  23. Lisle Nabell · 1 shared paper, 2023 · strength 0.18
  24. Sushanth Reddy · 1 shared paper, 2022 · strength 0.17
  25. Seifeldin Awad · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.